首页 > 最新文献

Journal of translational genetics and genomics最新文献

英文 中文
King syndrome: what’s in a name? 金综合症:名字里有什么?
Pub Date : 2021-03-26 DOI: 10.20517/JTGG.2021.17
Laurie M. Connors
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
©作者2021。开放获取本文根据知识共享署名4.0国际许可证获得许可(https://creativecommons.org/licenses/by/4.0/),允许以任何媒介或格式,出于任何目的,甚至商业目的,不受限制地使用、共享、改编、分发和复制,只要您对原作者和来源给予适当的信任,提供到知识共享许可证的链接,并说明是否进行了更改。
{"title":"King syndrome: what’s in a name?","authors":"Laurie M. Connors","doi":"10.20517/JTGG.2021.17","DOIUrl":"https://doi.org/10.20517/JTGG.2021.17","url":null,"abstract":"© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42617198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydroxyurea treatment of sickle cell disease: towards a personalized model-based approach 羟基脲治疗镰状细胞病:基于个性化模型的方法
Pub Date : 2021-01-26 DOI: 10.20517/JTGG.2020.45
A. Pandey, J. Estepp, D. Ramkrishna
Hydroxyurea is a commonly used drug for the treatment of sickle cell disease. Several studies have demonstrated the efficacy of hydroxyurea in ameliorating disease pathophysiology. However, a lack of consensus on optimal dosing and the need for ongoing toxicity monitoring for myelosuppression limits its utilization. Pharmacokinetic (PK) and pharmacodynamic (PD) studies describe drug-body interactions, and hydroxyurea PK-PD studies have reported wide inter-patient variability. This variability can be explained by a mathematical model taking into consideration different sources of variation such as genetics, epigenetics, phenotypes, and demographics. A PK-PD model provides us with a tool to capture these variant responses of patients to a given drug. The development of an integrated population PK-PD model that can predict individual patient responses and identify optimal dosing would maximize efficacy, limit toxicity, and increase utilization. In this review, we discuss various treatment challenges associated with hydroxyurea. We summarize existing population PK-PD models of hydroxyurea, the gap in the existing models, and the gap in the mechanistic understanding. Lastly, we address how mathematical modeling can be applied to improve our understanding of hydroxyurea’s mechanism of action and to tackle the challenge of interpatient variability, dose optimization, and non-adherence.
羟基脲是治疗镰状细胞病的常用药物。几项研究已经证明羟基脲在改善疾病病理生理学方面的疗效。然而,对最佳给药缺乏共识,并且需要对骨髓抑制进行持续的毒性监测,限制了其使用。药代动力学(PK)和药效学(PD)研究描述了药体相互作用,羟基脲PK-PD研究报告了广泛的患者间变异性。这种变异性可以通过数学模型来解释,该模型考虑了不同的变异来源,如遗传学、表观遗传学、表型和人口统计学。PK-PD模型为我们提供了一种工具来捕捉患者对给定药物的这些变异反应。开发一种能够预测个体患者反应并确定最佳给药的综合人群PK-PD模型,将最大限度地提高疗效、限制毒性并提高利用率。在这篇综述中,我们讨论了与羟基脲相关的各种治疗挑战。我们总结了羟基脲的现有群体PK-PD模型、现有模型中的差距以及对机制理解的差距。最后,我们讨论了如何应用数学建模来提高我们对羟基脲作用机制的理解,并应对患者间变异性、剂量优化和不依从性的挑战。
{"title":"Hydroxyurea treatment of sickle cell disease: towards a personalized model-based approach","authors":"A. Pandey, J. Estepp, D. Ramkrishna","doi":"10.20517/JTGG.2020.45","DOIUrl":"https://doi.org/10.20517/JTGG.2020.45","url":null,"abstract":"Hydroxyurea is a commonly used drug for the treatment of sickle cell disease. Several studies have demonstrated the efficacy of hydroxyurea in ameliorating disease pathophysiology. However, a lack of consensus on optimal dosing and the need for ongoing toxicity monitoring for myelosuppression limits its utilization. Pharmacokinetic (PK) and pharmacodynamic (PD) studies describe drug-body interactions, and hydroxyurea PK-PD studies have reported wide inter-patient variability. This variability can be explained by a mathematical model taking into consideration different sources of variation such as genetics, epigenetics, phenotypes, and demographics. A PK-PD model provides us with a tool to capture these variant responses of patients to a given drug. The development of an integrated population PK-PD model that can predict individual patient responses and identify optimal dosing would maximize efficacy, limit toxicity, and increase utilization. In this review, we discuss various treatment challenges associated with hydroxyurea. We summarize existing population PK-PD models of hydroxyurea, the gap in the existing models, and the gap in the mechanistic understanding. Lastly, we address how mathematical modeling can be applied to improve our understanding of hydroxyurea’s mechanism of action and to tackle the challenge of interpatient variability, dose optimization, and non-adherence.","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43346167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases. 前列腺癌在年轻男性代表一个独特的临床表型:基因表达特征预测早期转移。
Pub Date : 2021-01-01 Epub Date: 2021-03-09 DOI: 10.20517/jtgg.2021.01
Yuan C Ding, Huiqing Wu, Elai Davicioni, R Jeffrey Karnes, Eric A Klein, Robert B Den, Linda Steele, Susan L Neuhausen

Aim: Several genomic signatures are available to predict Prostate Cancer (CaP) outcomes based on gene expression in prostate tissue. However, no signature was tailored to predict aggressive CaP in younger men. We attempted to develop a gene signature to predict the development of metastatic CaP in young men.

Methods: We measured genome-wide gene expression for 119 tumor and matched benign tissues from prostatectomies of men diagnosed at ≤ 50 years and > 70 years and identified age-related differentially expressed genes (DEGs) for tissue type and Gleason score. Age-related DEGs were selected using the improved Prediction Analysis of Microarray method (iPAM) to construct and validate a classifier to predict metastasis using gene expression data from 1,232 prostatectomies. Accuracy in predicting early metastasis was quantified by the area under the curve (AUC) of receiver operating characteristic (ROC), and abundance of immune cells in the tissue microenvironment was estimated using gene expression data.

Results: Thirty-six age-related DEGs were selected for the iPAM classifier. The AUC of five-year survival ROC for the iPAM classifier was 0.87 (95%CI: 0.78-0.94) in young (≤ 55 years), 0.82 (95%CI: 0.76-0.88) in middle-aged (56-70 years), and 0.69 (95%CI: 0.55-0.69) in old (> 70 years) patients. Metastasis-associated immune responses in the tumor microenvironment were more pronounced in young and middle-aged patients than in old ones, potentially explaining the difference in accuracy of prediction among the groups.

Conclusion: We developed a genomic classifier with high precision to predict early metastasis for younger CaP patients and identified age-related differences in immune response to metastasis development.

目的:基于前列腺组织中基因表达的几个基因组特征可用于预测前列腺癌(CaP)的预后。然而,没有专门的特征来预测年轻男性的攻击性CaP。我们试图开发一种基因标记来预测年轻男性转移性CaP的发展。方法:我们测量了诊断年龄在≤50岁和> 70岁的男性前列腺切除术中119例肿瘤和匹配良性组织的全基因组基因表达,并确定了组织类型和Gleason评分的年龄相关差异表达基因(DEGs)。使用改进的微阵列预测分析方法(iPAM)选择年龄相关的deg,构建并验证分类器,利用1232例前列腺切除术的基因表达数据预测转移。通过受试者工作特征(ROC)曲线下面积(AUC)量化预测早期转移的准确性,并通过基因表达数据估计组织微环境中免疫细胞的丰度。结果:36个年龄相关的deg被选择用于iPAM分类器。iPAM分类器的5年生存ROC AUC在年轻(≤55岁)患者为0.87 (95%CI: 0.78-0.94),在中年(56-70岁)患者为0.82 (95%CI: 0.76-0.88),在老年(> 70岁)患者为0.69 (95%CI: 0.55-0.69)。肿瘤微环境中与转移相关的免疫反应在年轻和中年患者中比在老年患者中更为明显,这可能解释了两组之间预测准确性的差异。结论:我们开发了一种高精度的基因组分类器来预测年轻CaP患者的早期转移,并确定了转移发展中免疫反应的年龄相关差异。
{"title":"Prostate cancer in young men represents a distinct clinical phenotype: gene expression signature to predict early metastases.","authors":"Yuan C Ding,&nbsp;Huiqing Wu,&nbsp;Elai Davicioni,&nbsp;R Jeffrey Karnes,&nbsp;Eric A Klein,&nbsp;Robert B Den,&nbsp;Linda Steele,&nbsp;Susan L Neuhausen","doi":"10.20517/jtgg.2021.01","DOIUrl":"https://doi.org/10.20517/jtgg.2021.01","url":null,"abstract":"<p><strong>Aim: </strong>Several genomic signatures are available to predict Prostate Cancer (CaP) outcomes based on gene expression in prostate tissue. However, no signature was tailored to predict aggressive CaP in younger men. We attempted to develop a gene signature to predict the development of metastatic CaP in young men.</p><p><strong>Methods: </strong>We measured genome-wide gene expression for 119 tumor and matched benign tissues from prostatectomies of men diagnosed at ≤ 50 years and > 70 years and identified age-related differentially expressed genes (DEGs) for tissue type and Gleason score. Age-related DEGs were selected using the improved Prediction Analysis of Microarray method (iPAM) to construct and validate a classifier to predict metastasis using gene expression data from 1,232 prostatectomies. Accuracy in predicting early metastasis was quantified by the area under the curve (AUC) of receiver operating characteristic (ROC), and abundance of immune cells in the tissue microenvironment was estimated using gene expression data.</p><p><strong>Results: </strong>Thirty-six age-related DEGs were selected for the iPAM classifier. The AUC of five-year survival ROC for the iPAM classifier was 0.87 (95%CI: 0.78-0.94) in young (≤ 55 years), 0.82 (95%CI: 0.76-0.88) in middle-aged (56-70 years), and 0.69 (95%CI: 0.55-0.69) in old (> 70 years) patients. Metastasis-associated immune responses in the tumor microenvironment were more pronounced in young and middle-aged patients than in old ones, potentially explaining the difference in accuracy of prediction among the groups.</p><p><strong>Conclusion: </strong>We developed a genomic classifier with high precision to predict early metastasis for younger CaP patients and identified age-related differences in immune response to metastasis development.</p>","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":" ","pages":"50-61"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38933706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma Talimogene laherparepvec和新型注射溶瘤病毒在转移性黑色素瘤治疗中的作用
Pub Date : 2021-01-01 DOI: 10.20517/jtgg.2021.29
Frances G. Jenkins, J.E. Johnson, F. Collichio, D. Ollila
and viruses Abstract Talimogene laherparepvec (T-VEC) is an oncolytic virus (OV) therapy derived from the JS1 strain of herpes simplex virus one that was approved by the Food and Drug Administration in 2015 to be administered as direct injection therapy for patients with melanoma. The anti-tumor effects of T-VEC are due to viral-mediated tumor cell lysis at the site of administration and a local, and in some cases systemic, anti-tumor response via T cell-mediated host immune response pathways aided by GM-CSF. T-VEC has shown promising results for metastatic melanoma, particularly in patients with skin, lymph node, and soft tissue metastases (stages IIIB, IIIC, and IVa). Studies have explored the utility of T-VEC as monotherapy, neoadjuvant therapy, and in combination with other immunotherapies and targeted therapies. T-VEC has proven to improve durable response rates and overall survival with a very tolerable safety profile. More research is needed to better understand which patients are most likely to benefit from T-VEC therapy, which combination therapies are most effective, and how to sequence multimodality therapy. Additionally, new OVs are currently in development and/or being studied in clinical trials. In this review, we will discuss T-VEC as a monotherapy, neoadjuvant therapy, and combination therapy, in addition to future directions for melanoma therapy as it pertains to new OVs. progression-free survival longer recruiting patients. The estimated completion date is in January 2022. Finally, a non-randomized, open-label, multicenter phase 1b/2 trial (MASTERKEY-318) is assessing the efficacy and safety of intratumoral T-VEC in liver tumors as either monotherapy or in combination with pembrolizumab [43] . The study involves two groups of patients, distinguished based on the underlying disease. Group A will involve patients with non-hepatocellular carcinoma (HCC) liver metastases, including melanoma. Group B will include patients with HCC. This study is currently recruiting patients and has an estimated completion date of October 25, 2022.
T-VEC (Talimogene laherparepvec, T-VEC)是一种溶瘤病毒(OV)疗法,衍生自单纯疱疹病毒JS1株,于2015年获得美国食品和药物管理局批准,可作为黑色素瘤患者的直接注射治疗药物。T- vec的抗肿瘤作用是由于给药部位的病毒介导的肿瘤细胞裂解和局部的,在某些情况下,通过GM-CSF辅助的T细胞介导的宿主免疫反应途径产生全身的抗肿瘤反应。T-VEC在转移性黑色素瘤治疗中显示出良好的效果,特别是在皮肤、淋巴结和软组织转移(IIIB、IIIC和IVa期)的患者中。研究已经探索了T-VEC作为单一疗法、新辅助疗法以及与其他免疫疗法和靶向疗法联合使用的效用。T-VEC已被证明可以提高持久的反应率和总体生存率,并具有非常可容忍的安全性。需要更多的研究来更好地了解哪些患者最有可能从T-VEC治疗中获益,哪种联合治疗最有效,以及如何对多模式治疗进行排序。此外,新的OVs目前正在开发和/或正在临床试验中进行研究。在这篇综述中,我们将讨论T-VEC作为单一治疗,新辅助治疗和联合治疗,以及黑色素瘤治疗的未来方向,因为它与新的OVs有关。招募患者的无进展生存期更长。预计完工日期为2022年1月。最后,一项非随机、开放标签、多中心1b/2期试验(MASTERKEY-318)正在评估肿瘤内T-VEC作为单药治疗或联合派姆单抗[43]治疗肝脏肿瘤的疗效和安全性。该研究涉及两组患者,根据潜在疾病进行区分。A组将包括非肝细胞癌(HCC)肝转移患者,包括黑色素瘤。B组包括HCC患者。该研究目前正在招募患者,预计完成日期为2022年10月25日。
{"title":"Talimogene laherparepvec and novel injectable oncolytic viruses in the management of metastatic melanoma","authors":"Frances G. Jenkins, J.E. Johnson, F. Collichio, D. Ollila","doi":"10.20517/jtgg.2021.29","DOIUrl":"https://doi.org/10.20517/jtgg.2021.29","url":null,"abstract":"and viruses Abstract Talimogene laherparepvec (T-VEC) is an oncolytic virus (OV) therapy derived from the JS1 strain of herpes simplex virus one that was approved by the Food and Drug Administration in 2015 to be administered as direct injection therapy for patients with melanoma. The anti-tumor effects of T-VEC are due to viral-mediated tumor cell lysis at the site of administration and a local, and in some cases systemic, anti-tumor response via T cell-mediated host immune response pathways aided by GM-CSF. T-VEC has shown promising results for metastatic melanoma, particularly in patients with skin, lymph node, and soft tissue metastases (stages IIIB, IIIC, and IVa). Studies have explored the utility of T-VEC as monotherapy, neoadjuvant therapy, and in combination with other immunotherapies and targeted therapies. T-VEC has proven to improve durable response rates and overall survival with a very tolerable safety profile. More research is needed to better understand which patients are most likely to benefit from T-VEC therapy, which combination therapies are most effective, and how to sequence multimodality therapy. Additionally, new OVs are currently in development and/or being studied in clinical trials. In this review, we will discuss T-VEC as a monotherapy, neoadjuvant therapy, and combination therapy, in addition to future directions for melanoma therapy as it pertains to new OVs. progression-free survival longer recruiting patients. The estimated completion date is in January 2022. Finally, a non-randomized, open-label, multicenter phase 1b/2 trial (MASTERKEY-318) is assessing the efficacy and safety of intratumoral T-VEC in liver tumors as either monotherapy or in combination with pembrolizumab [43] . The study involves two groups of patients, distinguished based on the underlying disease. Group A will involve patients with non-hepatocellular carcinoma (HCC) liver metastases, including melanoma. Group B will include patients with HCC. This study is currently recruiting patients and has an estimated completion date of October 25, 2022.","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67658440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma. NK 细胞在溶瘤病毒疗法中的作用:聚焦肝细胞癌。
Pub Date : 2021-01-01 Epub Date: 2021-08-04 DOI: 10.20517/jtgg.2021.27
Frazer Warricker, Salim I Khakoo, Matthew D Blunt

Natural killer (NK) cells have a key role in host anti-tumour immune responses via direct killing of tumour cells and promotion of adaptive immune responses. They are therefore attractive targets to promote the anti-tumour efficacy of oncolytic viral therapies. However, NK cells are also potent components of the host anti-viral immune response, and therefore have the potential for detrimental anti-viral responses, limiting the spread and persistence of oncolytic viruses. Oncolytic viruses are currently being investigated for the treatment of hepatocellular carcinoma (HCC), a leading cause of cancer-related death with a high unmet clinical need. In this review, we highlight the role of NK cells in oncolytic virus therapy, their potential for improving treatment options for patients with HCC, and discuss current and potential strategies targeting NK cells in combination with oncolytic viral therapies.

自然杀伤(NK)细胞通过直接杀伤肿瘤细胞和促进适应性免疫反应,在宿主抗肿瘤免疫反应中发挥着关键作用。因此,它们是促进溶瘤病毒疗法抗肿瘤疗效的诱人靶点。不过,NK 细胞也是宿主抗病毒免疫反应的有效组成部分,因此有可能产生有害的抗病毒反应,限制溶瘤病毒的传播和持续存在。溶瘤病毒目前正被研究用于治疗肝细胞癌(HCC),这是癌症相关死亡的主要原因之一,但临床需求尚未得到满足。在这篇综述中,我们将重点介绍 NK 细胞在溶瘤病毒疗法中的作用、其改善 HCC 患者治疗方案的潜力,并讨论针对 NK 细胞与溶瘤病毒疗法相结合的现有和潜在策略。
{"title":"The role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma.","authors":"Frazer Warricker, Salim I Khakoo, Matthew D Blunt","doi":"10.20517/jtgg.2021.27","DOIUrl":"10.20517/jtgg.2021.27","url":null,"abstract":"<p><p>Natural killer (NK) cells have a key role in host anti-tumour immune responses via direct killing of tumour cells and promotion of adaptive immune responses. They are therefore attractive targets to promote the anti-tumour efficacy of oncolytic viral therapies. However, NK cells are also potent components of the host anti-viral immune response, and therefore have the potential for detrimental anti-viral responses, limiting the spread and persistence of oncolytic viruses. Oncolytic viruses are currently being investigated for the treatment of hepatocellular carcinoma (HCC), a leading cause of cancer-related death with a high unmet clinical need. In this review, we highlight the role of NK cells in oncolytic virus therapy, their potential for improving treatment options for patients with HCC, and discuss current and potential strategies targeting NK cells in combination with oncolytic viral therapies.</p>","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":" ","pages":"304-322"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7612080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39712055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. 四种非霍奇金淋巴瘤亚型的全基因组纯合性和风险。
Pub Date : 2021-01-01 Epub Date: 2021-06-17 DOI: 10.20517/jtgg.2021.08
Amy Moore, Mitchell J Machiela, Moara Machado, Sophia S Wang, Eleanor Kane, Susan L Slager, Weiyin Zhou, Mary Carrington, Qing Lan, Roger L Milne, Brenda M Birmann, Hans-Olov Adami, Demetrius Albanes, Alan A Arslan, Nikolaus Becker, Yolanda Benavente, Simonetta Bisanzi, Paolo Boffetta, Paige M Bracci, Paul Brennan, Angela R Brooks-Wilson, Federico Canzian, Neil Caporaso, Jacqueline Clavel, Pierluigi Cocco, Lucia Conde, David G Cox, Wendy Cozen, Karen Curtin, Immaculata De Vivo, Silvia de Sanjose, Lenka Foretova, Susan M Gapstur, Hervè Ghesquières, Graham G Giles, Martha Glenn, Bengt Glimelius, Chi Gao, Thomas M Habermann, Henrik Hjalgrim, Rebecca D Jackson, Mark Liebow, Brian K Link, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Thierry J Molina, Alain Monnereau, Alexandra Nieters, Kari E North, Kenneth Offit, Alpa V Patel, Sara Piro, Vignesh Ravichandran, Elio Riboli, Gilles Salles, Richard K Severson, Christine F Skibola, Karin E Smedby, Melissa C Southey, John J Spinelli, Anthony Staines, Carolyn Stewart, Lauren R Teras, Lesley F Tinker, Ruth C Travis, Claire M Vajdic, Roel C H Vermeulen, Joseph Vijai, Elisabete Weiderpass, Stephanie Weinstein, Nicole Wong Doo, Yawei Zhang, Tongzhang Zheng, Stephen J Chanock, Nathaniel Rothman, James R Cerhan, Michael Dean, Nicola J Camp, Meredith Yeager, Sonja I Berndt

Aim: Recessive genetic variation is thought to play a role in non-Hodgkin lymphoma (NHL) etiology. Runs of homozygosity (ROH), defined based on long, continuous segments of homozygous SNPs, can be used to estimate both measured and unmeasured recessive genetic variation. We sought to examine genome-wide homozygosity and NHL risk.

Methods: We used data from eight genome-wide association studies of four common NHL subtypes: 3061 chronic lymphocytic leukemia (CLL), 3814 diffuse large B-cell lymphoma (DLBCL), 2784 follicular lymphoma (FL), and 808 marginal zone lymphoma (MZL) cases, as well as 9374 controls. We examined the effect of homozygous variation on risk by: (1) estimating the fraction of the autosome containing runs of homozygosity (FROH); (2) calculating an inbreeding coefficient derived from the correlation among uniting gametes (F3); and (3) examining specific autosomal regions containing ROH. For each, we calculated beta coefficients and standard errors using logistic regression and combined estimates across studies using random-effects meta-analysis.

Results: We discovered positive associations between FROH and CLL (β = 21.1, SE = 4.41, P = 1.6 × 10-6) and FL (β = 11.4, SE = 5.82, P = 0.02) but not DLBCL (P = 1.0) or MZL (P = 0.91). For F3, we observed an association with CLL (β = 27.5, SE = 6.51, P = 2.4 × 10-5). We did not find evidence of associations with specific ROH, suggesting that the associations observed with FROH and F3 for CLL and FL risk were not driven by a single region of homozygosity.

Conclusion: Our findings support the role of recessive genetic variation in the etiology of CLL and FL; additional research is needed to identify the specific loci associated with NHL risk.

目的:隐性遗传变异被认为在非霍奇金淋巴瘤(NHL)病因中起作用。纯合性(ROH)是基于纯合SNPs的长、连续片段定义的,可用于估计测量和未测量的隐性遗传变异。我们试图检测全基因组纯合性和NHL风险。方法:我们使用了来自四种常见NHL亚型的八项全基因组关联研究的数据:3061例慢性淋巴细胞白血病(CLL)、3814例弥漫性大B细胞淋巴瘤(DLBCL)、2784例滤泡性淋巴瘤(FL)和808例边缘区淋巴瘤(MZL)病例,以及9374例对照。我们通过以下方法检测了纯合变异对风险的影响:(1)估计含有纯合性(FROH)的常染色体的比例;(2) 计算从合并配子之间的相关性导出的近亲繁殖系数(F3);和(3)检测含有ROH的特异性常染色体区域。对于每种情况,我们使用逻辑回归和使用随机效应荟萃分析的研究组合估计来计算β系数和标准误差。结果:我们发现FROH和CLL(β=21.1,SE=4.41,P=1.6×10-6)与FL(β=11.4,SE=5.82,P=0.02)之间存在正相关,但DLBCL(P=1.0)或MZL(P=0.91)除外。对于F3,我们观察到与CLL相关(β=27.5,SE=6.51,P=2.4×10-5)。我们没有发现与特定ROH相关的证据,这表明用FROH和F3观察到的CLL和FL风险的相关性不是由单一的纯合性区域驱动的。结论:我们的研究结果支持隐性遗传变异在CLL和FL病因中的作用;需要更多的研究来确定与NHL风险相关的特定基因座。
{"title":"Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes.","authors":"Amy Moore, Mitchell J Machiela, Moara Machado, Sophia S Wang, Eleanor Kane, Susan L Slager, Weiyin Zhou, Mary Carrington, Qing Lan, Roger L Milne, Brenda M Birmann, Hans-Olov Adami, Demetrius Albanes, Alan A Arslan, Nikolaus Becker, Yolanda Benavente, Simonetta Bisanzi, Paolo Boffetta, Paige M Bracci, Paul Brennan, Angela R Brooks-Wilson, Federico Canzian, Neil Caporaso, Jacqueline Clavel, Pierluigi Cocco, Lucia Conde, David G Cox, Wendy Cozen, Karen Curtin, Immaculata De Vivo, Silvia de Sanjose, Lenka Foretova, Susan M Gapstur, Hervè Ghesquières, Graham G Giles, Martha Glenn, Bengt Glimelius, Chi Gao, Thomas M Habermann, Henrik Hjalgrim, Rebecca D Jackson, Mark Liebow, Brian K Link, Marc Maynadie, James McKay, Mads Melbye, Lucia Miligi, Thierry J Molina, Alain Monnereau, Alexandra Nieters, Kari E North, Kenneth Offit, Alpa V Patel, Sara Piro, Vignesh Ravichandran, Elio Riboli, Gilles Salles, Richard K Severson, Christine F Skibola, Karin E Smedby, Melissa C Southey, John J Spinelli, Anthony Staines, Carolyn Stewart, Lauren R Teras, Lesley F Tinker, Ruth C Travis, Claire M Vajdic, Roel C H Vermeulen, Joseph Vijai, Elisabete Weiderpass, Stephanie Weinstein, Nicole Wong Doo, Yawei Zhang, Tongzhang Zheng, Stephen J Chanock, Nathaniel Rothman, James R Cerhan, Michael Dean, Nicola J Camp, Meredith Yeager, Sonja I Berndt","doi":"10.20517/jtgg.2021.08","DOIUrl":"10.20517/jtgg.2021.08","url":null,"abstract":"<p><strong>Aim: </strong>Recessive genetic variation is thought to play a role in non-Hodgkin lymphoma (NHL) etiology. Runs of homozygosity (ROH), defined based on long, continuous segments of homozygous SNPs, can be used to estimate both measured and unmeasured recessive genetic variation. We sought to examine genome-wide homozygosity and NHL risk.</p><p><strong>Methods: </strong>We used data from eight genome-wide association studies of four common NHL subtypes: 3061 chronic lymphocytic leukemia (CLL), 3814 diffuse large B-cell lymphoma (DLBCL), 2784 follicular lymphoma (FL), and 808 marginal zone lymphoma (MZL) cases, as well as 9374 controls. We examined the effect of homozygous variation on risk by: (1) estimating the fraction of the autosome containing runs of homozygosity (FROH); (2) calculating an inbreeding coefficient derived from the correlation among uniting gametes (F3); and (3) examining specific autosomal regions containing ROH. For each, we calculated beta coefficients and standard errors using logistic regression and combined estimates across studies using random-effects meta-analysis.</p><p><strong>Results: </strong>We discovered positive associations between FROH and CLL (β = 21.1, SE = 4.41, <i>P</i> = 1.6 × 10<sup>-6</sup>) and FL (β = 11.4, SE = 5.82, <i>P</i> = 0.02) but not DLBCL (<i>P</i> = 1.0) or MZL (<i>P</i> = 0.91). For F3, we observed an association with CLL (β = 27.5, SE = 6.51, <i>P</i> = 2.4 × 10<sup>-5</sup>). We did not find evidence of associations with specific ROH, suggesting that the associations observed with FROH and F3 for CLL and FL risk were not driven by a single region of homozygosity.</p><p><strong>Conclusion: </strong>Our findings support the role of recessive genetic variation in the etiology of CLL and FL; additional research is needed to identify the specific loci associated with NHL risk.</p>","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":"5 ","pages":"200-217"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8494431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10218204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Toward uncharted territory of cellular heterogeneity: advances and applications of single-cell RNA-seq. 迈向细胞异质性的未知领域:单细胞 RNA-seq 的进展与应用。
Pub Date : 2021-01-01 DOI: 10.20517/jtgg.2020.51
Brandon Lieberman, Meena Kusi, Chia-Nung Hung, Chih-Wei Chou, Ning He, Yen-Yi Ho, Josephine A Taverna, Tim H M Huang, Chun-Liang Chen

Among single-cell analysis technologies, single-cell RNA-seq (scRNA-seq) has been one of the front runners in technical inventions. Since its induction, scRNA-seq has been well received and undergone many fast-paced technical improvements in cDNA synthesis and amplification, processing and alignment of next generation sequencing reads, differentially expressed gene calling, cell clustering, subpopulation identification, and developmental trajectory prediction. scRNA-seq has been exponentially applied to study global transcriptional profiles in all cell types in humans and animal models, healthy or with diseases, including cancer. Accumulative novel subtypes and rare subpopulations have been discovered as potential underlying mechanisms of stochasticity, differentiation, proliferation, tumorigenesis, and aging. scRNA-seq has gradually revealed the uncharted territory of cellular heterogeneity in transcriptomes and developed novel therapeutic approaches for biomedical applications. This review of the advancement of scRNA-seq methods provides an exploratory guide of the quickly evolving technical landscape and insights of focused features and strengths in each prominent area of progress.

在单细胞分析技术中,单细胞 RNA-seq(scRNA-seq)一直是技术发明的领跑者之一。自问世以来,scRNA-seq 在 cDNA 合成和扩增、新一代测序读数的处理和比对、差异表达基因调用、细胞聚类、亚群识别和发育轨迹预测等方面广受好评,并经历了许多快速的技术改进。scRNA-seq 已逐渐揭示了转录组中细胞异质性的未知领域,并为生物医学应用开发了新的治疗方法。这篇关于 scRNA-seq 方法进展的综述为快速发展的技术领域提供了探索性指南,并对每个突出进展领域的重点特征和优势进行了深入分析。
{"title":"Toward uncharted territory of cellular heterogeneity: advances and applications of single-cell RNA-seq.","authors":"Brandon Lieberman, Meena Kusi, Chia-Nung Hung, Chih-Wei Chou, Ning He, Yen-Yi Ho, Josephine A Taverna, Tim H M Huang, Chun-Liang Chen","doi":"10.20517/jtgg.2020.51","DOIUrl":"10.20517/jtgg.2020.51","url":null,"abstract":"<p><p>Among single-cell analysis technologies, single-cell RNA-seq (scRNA-seq) has been one of the front runners in technical inventions. Since its induction, scRNA-seq has been well received and undergone many fast-paced technical improvements in cDNA synthesis and amplification, processing and alignment of next generation sequencing reads, differentially expressed gene calling, cell clustering, subpopulation identification, and developmental trajectory prediction. scRNA-seq has been exponentially applied to study global transcriptional profiles in all cell types in humans and animal models, healthy or with diseases, including cancer. Accumulative novel subtypes and rare subpopulations have been discovered as potential underlying mechanisms of stochasticity, differentiation, proliferation, tumorigenesis, and aging. scRNA-seq has gradually revealed the uncharted territory of cellular heterogeneity in transcriptomes and developed novel therapeutic approaches for biomedical applications. This review of the advancement of scRNA-seq methods provides an exploratory guide of the quickly evolving technical landscape and insights of focused features and strengths in each prominent area of progress.</p>","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":" ","pages":"1-21"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8315474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39255041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developmental and epileptic encephalopathies after negative or inconclusive genetic testing: what is next? 基因检测阴性或不确定后的发展性和癫痫性脑病:下一步是什么?
Pub Date : 2021-01-01 DOI: 10.20517/jtgg.2021.40
Á. Aledo-Serrano, R. Sánchez‐Alcudia, R. Toledano, I. García-Morales, Á. Beltrán-Corbellini, Isabel del Pino, A. Gil-Nagel
The redefinition of classical electroclinical syndromes and the emergence of neurogenetics has led to a revolution in the field of developmental and epileptic encephalopathies (DEEs). In this context, advances in genetic techniques are leading to the final diagnosis of a large proportion of patients with DEE. However, up to 50% of patients with DEE remain undiagnosed. For patients with uncertain genetic etiology, there is a pressing need for the implementation of new targeted treatments and precision medicine. In some undiagnosed patients, genetic reanalysis with further in-depth or reverse phenotyping are valuable diagnostic tools to clarify new variants of uncertain significance. In other cases, the implementation of new bioinformatic algorithms is required for the update and reassessment of previously generated genetic data. Moreover, many other clinical tools have been developed for the management of patients of DEEs after a negative or inconclusive genetic testing. In this review, we highlight advances and limitations of new diagnostic strategies used in DEE patients without a known genetic etiology. Finally, we provide a wide perspective on aspects that will need further research, especially in non-Mendelian inheritance DEEs, such as those related to somatic mosaicism of the central nervous system or epigenetic and oligogenic mechanisms.
经典电临床综合征的重新定义和神经遗传学的出现导致了发育性和癫痫性脑病(dee)领域的革命。在这种情况下,遗传技术的进步正在导致很大比例的DEE患者的最终诊断。然而,高达50%的DEE患者仍未得到诊断。对于遗传病因不确定的患者,迫切需要实施新的靶向治疗和精准医疗。在一些未确诊的患者中,进一步深入或反向表型的基因再分析是有价值的诊断工具,以澄清不确定意义的新变异。在其他情况下,需要实施新的生物信息学算法来更新和重新评估以前生成的遗传数据。此外,已经开发了许多其他临床工具,用于管理阴性或不确定基因检测后的dei患者。在这篇综述中,我们强调了用于没有已知遗传病因的DEE患者的新诊断策略的进展和局限性。最后,我们对需要进一步研究的方面提供了广泛的视角,特别是在非孟德尔遗传方面,例如与中枢神经系统的体细胞嵌合体或表观遗传和少生机制有关的研究。
{"title":"Developmental and epileptic encephalopathies after negative or inconclusive genetic testing: what is next?","authors":"Á. Aledo-Serrano, R. Sánchez‐Alcudia, R. Toledano, I. García-Morales, Á. Beltrán-Corbellini, Isabel del Pino, A. Gil-Nagel","doi":"10.20517/jtgg.2021.40","DOIUrl":"https://doi.org/10.20517/jtgg.2021.40","url":null,"abstract":"The redefinition of classical electroclinical syndromes and the emergence of neurogenetics has led to a revolution in the field of developmental and epileptic encephalopathies (DEEs). In this context, advances in genetic techniques are leading to the final diagnosis of a large proportion of patients with DEE. However, up to 50% of patients with DEE remain undiagnosed. For patients with uncertain genetic etiology, there is a pressing need for the implementation of new targeted treatments and precision medicine. In some undiagnosed patients, genetic reanalysis with further in-depth or reverse phenotyping are valuable diagnostic tools to clarify new variants of uncertain significance. In other cases, the implementation of new bioinformatic algorithms is required for the update and reassessment of previously generated genetic data. Moreover, many other clinical tools have been developed for the management of patients of DEEs after a negative or inconclusive genetic testing. In this review, we highlight advances and limitations of new diagnostic strategies used in DEE patients without a known genetic etiology. Finally, we provide a wide perspective on aspects that will need further research, especially in non-Mendelian inheritance DEEs, such as those related to somatic mosaicism of the central nervous system or epigenetic and oligogenic mechanisms.","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67658098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Roles of interacting stress-related genes in lifespan regulation: insights for translating experimental findings to humans. 相互影响的压力相关基因在寿命调节中的作用:将实验结果转化为人类的启示。
Pub Date : 2021-01-01 Epub Date: 2021-10-19
Anatoliy I Yashin, Deqing Wu, Konstantin Arbeev, Arseniy P Yashkin, Igor Akushevich, Olivia Bagley, Matt Duan, Svetlana Ukraintseva

Aim: Experimental studies provided numerous evidence that caloric/dietary restriction may improve health and increase the lifespan of laboratory animals, and that the interplay among molecules that sense cellular stress signals and those regulating cell survival can play a crucial role in cell response to nutritional stressors. However, it is unclear whether the interplay among corresponding genes also plays a role in human health and lifespan.

Methods: Literature about roles of cellular stressors have been reviewed, such as amino acid deprivation, and the integrated stress response (ISR) pathway in health and aging. Single nucleotide polymorphisms (SNPs) in two candidate genes (GCN2/EIF2AK4 and CHOP/DDIT3) that are closely involved in the cellular stress response to amino acid starvation, have been selected using information from experimental studies. Associations of these SNPs and their interactions with human survival in the Health and Retirement Study data have been estimated. The impact of collective associations of multiple interacting SNP pairs on survival has been evaluated, using a recently developed composite index: the SNP-specific Interaction Polygenic Risk Score (SIPRS).

Results: Significant interactions have been found between SNPs from GCN2/EIF2AK4 and CHOP/DDI3T genes that were associated with survival 85+ compared to survival between ages 75 and 85 in the total sample (males and females combined) and in females only. This may reflect sex differences in genetic regulation of the human lifespan. Highly statistically significant associations of SIPRS [constructed for the rs16970024 (GCN2/EIF2AK4) and rs697221 (CHOP/DDIT3)] with survival in both sexes also been found in this study.

Conclusion: Identifying associations of the genetic interactions with human survival is an important step in translating the knowledge from experimental to human aging research. Significant associations of multiple SNPxSNP interactions in ISR genes with survival to the oldest old age that have been found in this study, can help uncover mechanisms of multifactorial regulation of human lifespan and its heterogeneity.

目的:实验研究提供了大量证据,证明热量/饮食限制可改善实验动物的健康状况并延长其寿命,而且感知细胞压力信号的分子和调节细胞存活的分子之间的相互作用在细胞对营养压力源的反应中起着至关重要的作用。然而,目前还不清楚相应基因之间的相互作用是否也会对人类的健康和寿命产生影响:方法:对有关细胞应激源作用的文献进行了综述,如氨基酸剥夺和综合应激反应(ISR)途径在健康和衰老中的作用。根据实验研究的信息,筛选出了两个候选基因(GCN2/EIF2AK4 和 CHOP/DDIT3)中的单核苷酸多态性(SNPs),这两个基因与细胞对氨基酸饥饿的应激反应密切相关。在健康与退休研究(Health and Retirement Study)的数据中,对这些 SNPs 及其相互作用与人类生存的相关性进行了估算。利用最近开发的综合指数:SNP 特异性相互作用多基因风险评分(SIPRS),评估了多个相互作用 SNP 对生存的集体关联的影响:结果:GCN2/EIF2AK4 和 CHOP/DDI3T 基因的 SNP 之间存在显著的交互作用,这些 SNP 与总样本(男性和女性的总和)中 85 岁以上的存活率相比,与 75 至 85 岁的存活率相比,仅与女性的存活率相关。这可能反映了人类寿命基因调控的性别差异。本研究还发现,SIPRS[构建的rs16970024(GCN2/EIF2AK4)和rs697221(CHOP/DDIT3)]与两性的存活率存在高度统计学意义:结论:确定基因相互作用与人类生存的关联是将实验知识转化为人类衰老研究的重要一步。本研究中发现的 ISR 基因中多个 SNPxSNP 相互作用与高龄生存的显著关联,有助于揭示人类寿命的多因素调控机制及其异质性。
{"title":"Roles of interacting stress-related genes in lifespan regulation: insights for translating experimental findings to humans.","authors":"Anatoliy I Yashin, Deqing Wu, Konstantin Arbeev, Arseniy P Yashkin, Igor Akushevich, Olivia Bagley, Matt Duan, Svetlana Ukraintseva","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Aim: </strong>Experimental studies provided numerous evidence that caloric/dietary restriction may improve health and increase the lifespan of laboratory animals, and that the interplay among molecules that sense cellular stress signals and those regulating cell survival can play a crucial role in cell response to nutritional stressors. However, it is unclear whether the interplay among corresponding genes also plays a role in human health and lifespan.</p><p><strong>Methods: </strong>Literature about roles of cellular stressors have been reviewed, such as amino acid deprivation, and the integrated stress response (ISR) pathway in health and aging. Single nucleotide polymorphisms (SNPs) in two candidate genes (<i>GCN2/EIF2AK4</i> and <i>CHOP/DDIT3</i>) that are closely involved in the cellular stress response to amino acid starvation, have been selected using information from experimental studies. Associations of these SNPs and their interactions with human survival in the Health and Retirement Study data have been estimated. The impact of collective associations of multiple interacting SNP pairs on survival has been evaluated, using a recently developed composite index: the <i>SNP-specific Interaction Polygenic Risk Score</i> (SIPRS).</p><p><strong>Results: </strong>Significant interactions have been found between SNPs from <i>GCN2/EIF2AK4</i> and <i>CHOP/DDI3T</i> genes that were associated with survival 85+ compared to survival between ages 75 and 85 in the total sample (males and females combined) and in females only. This may reflect sex differences in genetic regulation of the human lifespan. Highly statistically significant associations of SIPRS [constructed for the rs16970024 (GCN2/EIF2AK4) and rs697221 (CHOP/DDIT3)] with survival in both sexes also been found in this study.</p><p><strong>Conclusion: </strong>Identifying associations of the genetic interactions with human survival is an important step in translating the knowledge from experimental to human aging research. Significant associations of multiple SNPxSNP interactions in ISR genes with survival to the oldest old age that have been found in this study, can help uncover mechanisms of multifactorial regulation of human lifespan and its heterogeneity.</p>","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":"5 4","pages":"357-379"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39928012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees. Duo-Shared基因组片段分析确定了骨髓瘤谱系中18q21.33的全基因组显著风险位点。
Pub Date : 2021-01-01 Epub Date: 2021-05-27 DOI: 10.20517/jtgg.2021.09
Rosalie Griffin Waller, Michael J Madsen, John Gardner, Douglas W Sborov, Nicola J Camp

Aim: High-risk pedigrees (HRPs) are a powerful design to map highly penetrant risk genes. We previously described Shared Genomic Segment (SGS) analysis, a mapping method for single large extended pedigrees that also addresses genetic heterogeneity inherent in complex diseases. SGS identifies shared segregating chromosomal regions that may inherit in only a subset of cases. However, single large pedigrees that are individually powerful (at least 15 meioses between studied cases) are scarce. Here, we expand the SGS strategy to incorporate evidence from two extended HRPs by identifying the same segregating risk locus in both pedigrees and allowing for some relaxation in the size of each HRP.

Methods: Duo-SGS is a procedure to combine single-pedigree SGS evidence. It implements statistically rigorous duo-pedigree thresholding to determine genome-wide significance levels that account for optimization across pedigree pairs. Single-pedigree SGS identifies optimal segments shared by case subsets at each locus across the genome, with nominal significance assessed empirically. Duo-SGS combines the statistical evidence for SGS segments at the same genomic location in two pedigrees using Fisher's method. One pedigree is paired with all others and the best duo-SGS evidence at each locus across the genome is established. Genome-wide significance thresholds are determined through distribution-fitting and the Theory of Large Deviations. We applied the duoSGS strategy to eleven extended, myeloma HRPs.

Results: We identified one genome-wide significant region at 18q21.33 (0.85 Mb, P = 7.3 × 10-9) which contains one gene, CDH20. Thirteen regions were genome-wide suggestive: 1q42.2, 2p16.1, 3p25.2, 5q21.3, 5q31.1, 6q16.1, 6q26, 7q11.23, 12q24.31, 13q13.3, 18p11.22, 18q22.3 and 19p13.12.

Conclusion: Our results provide novel risk loci with segregating evidence from multiple HRPs and offer compelling targets and specific segment carriers to focus a future search for functional variants involved in inherited risk formyeloma.

目的:高风险家系(HRPs)是绘制高渗透风险基因的有力设计。我们之前描述了共享基因组片段(SGS)分析,这是一种针对单个大型扩展谱系的作图方法,也解决了复杂疾病固有的遗传异质性。SGS识别了共享的分离染色体区域,这些区域可能只在一小部分病例中遗传。然而,单独强大的大型谱系(研究病例之间至少有15个减数分裂)很少。在这里,我们扩展了SGS策略,通过在两个谱系中识别相同的分离风险基因座,并允许每个HRP的大小有所放宽,将两个扩展的HRP的证据合并在一起。方法:Duo-SGS是一种合并单谱系SGS证据的程序。它实现了统计上严格的双谱系阈值,以确定全基因组显著性水平,从而解释谱系对之间的优化。单谱系SGS确定了基因组中每个基因座的病例亚群共享的最佳片段,并根据经验评估了标称显著性。Duo-SGS使用Fisher方法结合了两个谱系中相同基因组位置的SGS片段的统计证据。一个谱系与所有其他谱系配对,并在整个基因组的每个基因座建立最佳的双SGS证据。全基因组显著性阈值是通过分布拟合和大偏差理论确定的。我们将duoSGS策略应用于11个扩展的骨髓瘤HRP。结果:我们在18q21.33(0.85Mb,P=7.3×10-9)处鉴定出一个全基因组显著区域,该区域包含一个基因CDH20。13个区域是全基因组提示的:1q42.2、2p16.1、3p25.2、5q21.3、5qc31.1、6q16.1、6q26、7q11.23、12q24.31、13q13.3、18p11.22、18q22.3和19p13.12。
{"title":"Duo Shared Genomic Segment analysis identifies a genome-wide significant risk locus at 18q21.33 in myeloma pedigrees.","authors":"Rosalie Griffin Waller,&nbsp;Michael J Madsen,&nbsp;John Gardner,&nbsp;Douglas W Sborov,&nbsp;Nicola J Camp","doi":"10.20517/jtgg.2021.09","DOIUrl":"10.20517/jtgg.2021.09","url":null,"abstract":"<p><strong>Aim: </strong>High-risk pedigrees (<i>HRPs</i>) are a powerful design to map highly penetrant risk genes. We previously described Shared Genomic Segment (SGS) analysis, a mapping method for single large extended pedigrees that also addresses genetic heterogeneity inherent in complex diseases. SGS identifies shared segregating chromosomal regions that may inherit in only a subset of cases. However, single large pedigrees that are individually powerful (at least 15 meioses between studied cases) are scarce. Here, we expand the SGS strategy to incorporate evidence from two extended HRPs by identifying the same segregating risk locus in both pedigrees and allowing for some relaxation in the size of each HRP.</p><p><strong>Methods: </strong>Duo-SGS is a procedure to combine single-pedigree SGS evidence. It implements statistically rigorous duo-pedigree thresholding to determine genome-wide significance levels that account for optimization across pedigree pairs. Single-pedigree SGS identifies optimal segments shared by case subsets at each locus across the genome, with nominal significance assessed empirically. Duo-SGS combines the statistical evidence for SGS segments at the same genomic location in two pedigrees using Fisher's method. One pedigree is paired with all others and the best duo-SGS evidence at each locus across the genome is established. Genome-wide significance thresholds are determined through distribution-fitting and the Theory of Large Deviations. We applied the duoSGS strategy to eleven extended, myeloma HRPs.</p><p><strong>Results: </strong>We identified one genome-wide significant region at 18q21.33 (0.85 Mb, <i>P</i> = 7.3 × 10<sup>-9</sup>) which contains one gene, <i>CDH20</i>. Thirteen regions were genome-wide suggestive: 1q42.2, 2p16.1, 3p25.2, 5q21.3, 5q31.1, 6q16.1, 6q26, 7q11.23, 12q24.31, 13q13.3, 18p11.22, 18q22.3 and 19p13.12.</p><p><strong>Conclusion: </strong>Our results provide novel risk loci with segregating evidence from multiple HRPs and offer compelling targets and specific segment carriers to focus a future search for functional variants involved in inherited risk formyeloma.</p>","PeriodicalId":73999,"journal":{"name":"Journal of translational genetics and genomics","volume":"5 2","pages":"112-123"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8654160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39712056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of translational genetics and genomics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1